J Korean Ophthalmol Soc.  2009 Mar;50(3):331-335. 10.3341/jkos.2009.50.3.331.

Clinical Comparability of Dysport and Botox in Essential Blepharospasm

• Shin JH
• Jeon C
• Woo KI
• Kim YD

• KMID: 2111240
• DOI: http://doi.org/10.3341/jkos.2009.50.3.331

Abstract

PURPOSE: To compare the clinical efficacy, duration of effect, and safety of Dysport and Botox for patients with essential blepharospasm using functional disability scale.
METHODS
Patients with a confirmed diagnosis of essential blepharospasm who had received Botox (Allergan, USA) from September 2006 to May 2007 were enrolled in this study. We switched from Botox to Dysport (Ipsen, UK) after the botulinum effect of previous injection had disappeared and compared the clinical efficacy of two drugs. We used a 2.5:1 Dysport:Botox conversion ratio. The clinical efficacy of the drugs treatment was evaluated using a functional disability scale. We compared the duration of the effect and the safety of the two drugs.
RESULTS
The study included 48 patients (43 women, 5 men). There was no significant difference in mean functional disability scores or in any item of the functional disability scale. There was no significant difference in duration of effect between Botox (100.2+/-37.34 days) and Dysport (99.1+/-39.7days). There was also no significant difference in frequency of adverse reaction between Botox (13%) and Dysport (10%).
CONCLUSIONS
When a dose conversion of 2.5:1 Dysport:Botox was used for essential blepharospasm patients, the two drugs displayed almost identical clinical efficacy, duration of effect, and safety.

Keyword

Botulinum neurotoxin A; Conversion ratio; Essential blepharospasm

MeSH Terms

Blepharospasm
Botulinum Toxins, Type A
Female
Humans
Botulinum Toxins, Type A